Related Experiment Video
Updated: Oct 25, 2025

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies
Published on: November 10, 2023
[Environmental factors for the development of hematopoietic neoplasms in children]
Yuhki Koga1,2, Shunichiro Toya1, Masafumi Sanefuji1
1Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University.
Insights
Advanced parental age and prenatal medical irradiation correlate with increased pediatric cancer risk, particularly leukemia. Maternal exposure to anticancer drugs like cyclophosphamide also poses a risk, emphasizing the need for genotoxicity reduction.
Area of Science:
- Pediatric Oncology
- Environmental Epidemiology
- Cancer Genetics
Background:
- Parental age at birth is a known factor in various health outcomes.
- Previous studies have explored links between parental factors and pediatric cancer.
- The impact of prenatal exposures on childhood cancer development requires further investigation.
Purpose of the Study:
- To investigate the association between parental age at birth and pediatric cancer risk.
- To examine the role of prenatal medical irradiation in childhood leukemia.
- To assess caregiver exposure to anticancer drugs in pediatric cancer patients.
Main Methods:
- Analysis of the Japan Children's Cancer Registry data (1985-2007) for parental age effects.
- Cohort study of 27,335 patients (1969-2006) to assess prenatal irradiation.
- Biomonitoring of cyclophosphamide (CPM) in mothers and medical staff urine samples.
Main Results:
- Higher parental age (>40 years) showed a trend towards increased leukemia risk (OR 1.41).
- Infants born to mothers >40 years had a significantly higher leukemia risk (OR 2.55).
- Prenatal medical irradiation showed a statistically significant association with higher leukemia risk in earlier birth cohorts.
Conclusions:
- Advanced parental age and prenatal medical irradiation are potential risk factors for pediatric leukemia.
- Maternal exposure to anticancer drugs, such as cyclophosphamide, is a concern.
- Reducing genotoxicity in both infants and mothers is critical for pediatric cancer prevention.
Abstract:
Parental age at birth has been investigated in patients diagnosed with pediatric cancer. The Japan Children's Cancer Registry1985-2007 recruited 5,510 patients with leukemia and 8,782 with other cancers. The proportion of patients born to mother and father aged >40 years showed a higher trend in leukemia than that in other cancers (odds ratio [OR] 1.41, p=0.057), especially in <12-month-old infants born to mother aged >40 years (OR 2.55, p=0.031). We then divided 27,335 patients diagnosed in 1969-2006 into every 8-year birth cohorts to compare proportions of mothers with prenatal medical irradiation. The OR of leukemia was higher than that of other cancers in 1969-1976 (1.25) or 1977-1984 (1.39), which reached statistical significance. We have also studied caregiver's exposure to anticancer drugs. In 15 pediatric patients with cancer who received cyclophosphamide (CPM), the concentration was measured using mothers and medical staff's urine. Five of 7 infants' and 2 of 8 adolescent's mothers showed increased urine CPM levels. CPM was not detected in any medical staff's samples. Maternal exposure to anticancer drugs should also be considered. Efforts of reducing the genotoxicity in both infants and mothers are crucial for pediatric cancer prevention.
Related Concept Videos
Role of Hematopoietic Growth Factors
Thrombopoietin (TPO), mainly released by the liver,...
Regulation of Hematopoietic Stem Cells
Overview of Hematopoiesis
Developmental Phases of Hematopoiesis
Initially, HSCs are formed in the embryonic yolk sac, a critical site for early blood cell production. These stem cells subsequently migrate to other...
Hematopoiesis
Cancer Prevention
Some...
Factors Affecting Erythropoiesis
Several factors influence the erythrocyte production rate, with tissue oxygen level being among the most critical. Intense exercise or high altitudes can cause tissue hypoxia, which triggers the kidneys to release more erythropoietin (EPO) into the bloodstream.
EPO then...

